FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523034663> ?p ?o ?g. }

• W2523034663 abstract "Vision-related quality of life (vrQoL) is advancing more and more into the focus of interest in ophthalmological clinical research. However, to date only little information is available about vrQoL from large non-interventional studies in terms of real-world evidence. The purpose of this investigation was to describe baseline VFQ-25 visual function scores, to evaluate whether they differ from previous phase III clinical trials, to determine which contributing factors (e.g. indication, age, gender) affect VFQ-25 scores and to identify its impact on driving.The non-interventional OCEAN study (Observation of treatment patterns with LuCEntis and real life ophthalmic monitoring, including optional OCT in Approved iNdications) is the largest ophthalmic study conducted in Germany, to evaluate the real world situation of patients treated with ranibizumab (NCT02194803). The NEI-VFQ-25 questionnaire was conducted at baseline, months 4, 12 and 24. Descriptive statistics was used to analyse the baseline data. ANOVA was performed to evaluate the impact of various contributing factors on composite and selected subscale scores.Overall, 4844 (84.1 %) of all 5760 OCEAN patients completed the VFQ-25 questionnaire at baseline. Thereof, 3414 treatment-naïve patients were further analysed. Overall, the VFQ subscore general health was most affected by the ocular disease, followed by general vision. No major differences were detected in comparison to corresponding VFQ-25 scores of previous phase III clinical trials, except in DME patients, or with respect to possible contributing factors. A tendency towards a more decreased VFQ-25 composite score was observed for nAMD, for elderly patients ≥75 years of age, for female patients, for patients with low baseline visual acuity (VA; <50 letters) and for those with statutory health insurance. Indication, age, gender, baseline VA (all p <0.01) and the interaction of age and indication, as well as baseline VA and indication (p <0.01 each) had a significant impact on composite, general vision and distance vision scores (ANOVA). About 10 % of patients gave up driving due to eyesight issues.The knowledge of a patient's subjective disease burden is crucial to understanding anxieties and mental anguish. Additionally, the understanding of the impact of various contributing factors on the VFQ-25 scores and the extent to which they can be influenced help to optimize patient care. It demonstrates the need for medical and mental support by all medical staff, to encourage patients' compliance with a comprehensive anti-VEGF therapy, to increase BCVA and, consecutively, VFQ-25 scores.NCT02194803." @default.
• W2523034663 created "2016-09-30" @default.
• W2523034663 creator A5009841246 @default.
• W2523034663 creator A5014110974 @default.
• W2523034663 creator A5015160966 @default.
• W2523034663 creator A5027208147 @default.
• W2523034663 creator A5048237892 @default.
• W2523034663 creator A5050859090 @default.
• W2523034663 creator A5069429479 @default.
• W2523034663 date "2016-09-20" @default.
• W2523034663 modified "2023-10-14" @default.
• W2523034663 title "Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study" @default.
• W2523034663 cites W1532027413 @default.
• W2523034663 cites W1532515443 @default.
• W2523034663 cites W1560522926 @default.
• W2523034663 cites W1573398840 @default.
• W2523034663 cites W1580109412 @default.
• W2523034663 cites W164005972 @default.
• W2523034663 cites W1968756919 @default.
• W2523034663 cites W1970743643 @default.
• W2523034663 cites W1971593497 @default.
• W2523034663 cites W1974327301 @default.
• W2523034663 cites W1975883239 @default.
• W2523034663 cites W1979988382 @default.
• W2523034663 cites W1984287558 @default.
• W2523034663 cites W1984817372 @default.
• W2523034663 cites W1987082230 @default.
• W2523034663 cites W2003209902 @default.
• W2523034663 cites W2009592311 @default.
• W2523034663 cites W2011307681 @default.
• W2523034663 cites W2018021100 @default.
• W2523034663 cites W2024788461 @default.
• W2523034663 cites W2030972533 @default.
• W2523034663 cites W2035178655 @default.
• W2523034663 cites W2043591479 @default.
• W2523034663 cites W2051199531 @default.
• W2523034663 cites W2052553739 @default.
• W2523034663 cites W2052862964 @default.
• W2523034663 cites W2061893732 @default.
• W2523034663 cites W2065193247 @default.
• W2523034663 cites W2071672605 @default.
• W2523034663 cites W2076169604 @default.
• W2523034663 cites W2076727015 @default.
• W2523034663 cites W2077949459 @default.
• W2523034663 cites W2085712747 @default.
• W2523034663 cites W2092501667 @default.
• W2523034663 cites W2094707596 @default.
• W2523034663 cites W2096060458 @default.
• W2523034663 cites W2096257972 @default.
• W2523034663 cites W2101608645 @default.
• W2523034663 cites W2102946567 @default.
• W2523034663 cites W2117322871 @default.
• W2523034663 cites W2124415048 @default.
• W2523034663 cites W2128701654 @default.
• W2523034663 cites W2138697349 @default.
• W2523034663 cites W2146870005 @default.
• W2523034663 cites W2161279821 @default.
• W2523034663 cites W2162309497 @default.
• W2523034663 cites W2616361514 @default.
• W2523034663 cites W2767447900 @default.
• W2523034663 cites W3154357252 @default.
• W2523034663 cites W4317923773 @default.
• W2523034663 doi "https://doi.org/10.1186/s12955-016-0536-1" @default.
• W2523034663 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5029004" @default.
• W2523034663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27644469" @default.
• W2523034663 hasPublicationYear "2016" @default.
• W2523034663 type Work @default.
• W2523034663 sameAs 2523034663 @default.
• W2523034663 citedByCount "29" @default.
• W2523034663 countsByYear W25230346632017 @default.
• W2523034663 countsByYear W25230346632018 @default.
• W2523034663 countsByYear W25230346632019 @default.
• W2523034663 countsByYear W25230346632020 @default.
• W2523034663 countsByYear W25230346632021 @default.
• W2523034663 countsByYear W25230346632022 @default.
• W2523034663 countsByYear W25230346632023 @default.
• W2523034663 crossrefType "journal-article" @default.
• W2523034663 hasAuthorship W2523034663A5009841246 @default.
• W2523034663 hasAuthorship W2523034663A5014110974 @default.
• W2523034663 hasAuthorship W2523034663A5015160966 @default.
• W2523034663 hasAuthorship W2523034663A5027208147 @default.
• W2523034663 hasAuthorship W2523034663A5048237892 @default.
• W2523034663 hasAuthorship W2523034663A5050859090 @default.
• W2523034663 hasAuthorship W2523034663A5069429479 @default.
• W2523034663 hasBestOaLocation W25230346631 @default.
• W2523034663 hasConcept C105795698 @default.
• W2523034663 hasConcept C111368507 @default.
• W2523034663 hasConcept C118487528 @default.
• W2523034663 hasConcept C126322002 @default.
• W2523034663 hasConcept C12725497 @default.
• W2523034663 hasConcept C127313418 @default.
• W2523034663 hasConcept C159110408 @default.
• W2523034663 hasConcept C2776694085 @default.
• W2523034663 hasConcept C2777802072 @default.
• W2523034663 hasConcept C2779951463 @default.
• W2523034663 hasConcept C2781100027 @default.
• W2523034663 hasConcept C33923547 @default.
• W2523034663 hasConcept C39896193 @default.
• W2523034663 hasConcept C535046627 @default.
• W2523034663 hasConcept C71924100 @default.

• next